High drug payload nanoparticles formed from dexamethasone-peptide conjugates for the treatment of endotoxin-induced uveitis in rabbit

References

• ReddyAKEngelhardSBShahCTSimAJThorneJEMedical malpractice in uveitis: a review of clinical entities and outcomesOcul Immunol Inflamm201826224224827715388
   PubMed Web of Science ®Google Scholar
• SamudreSSLattanzioFAWilliamsPBSheppardJDComparison of topical steroids for acute anterior uveitisJ Ocul Pharmacol Ther200420653354715684812
   PubMed Web of Science ®Google Scholar
• MiserocchiEFogliatoGModoratiGBandelloFReview on the worldwide epidemiology of uveitisEur J Ophthalmol201323570571723661536
   PubMed Web of Science ®Google Scholar
• Rodríguez VillanuevaJRodríguez VillanuevaLGuzmán NavarroMVillanuevaJRVillanuevaLRNavarroMGPharmaceutical technology can turn a traditional drug, dexamethasone into a first-line ocular medicine. A global perspective and future trendsInt J Pharm20175161–234235127889587
   PubMed Web of Science ®Google Scholar
• GhasemiHRoles of IL-6 in Ocular Inflammation: A ReviewOcul Immunol Inflamm2018261375028146368
   PubMed Web of Science ®Google Scholar
• ImpellizzeriDAhmadABruschettaGThe anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in ratsEur J Pharmacol2015761283525934566
   PubMedGoogle Scholar
• LinPSuhlerEBRosenbaumJTThe future of uveitis treatmentOphthalmology2014121136537624169255
   PubMed Web of Science ®Google Scholar
• ZhengCLeiCChenZTopical administration of diminazene aceturate decreases inflammation in endotoxin-induced uveitisMol Vis20152140325883526
   PubMedGoogle Scholar
• CaoJNaeemMNohJ-KLeeEHYooJWDexamethasone phosphate-loaded folate-conjugated polymeric nanoparticles for selective delivery to activated macrophages and suppression of inflammatory responsesMacromol Res2015235485492
   Web of Science ®Google Scholar
• Barbosa SalibaJVieiraLFernandes-CunhaGMAnti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in RatsInvest Ophthalmol Vis Sci20165741671167927054520
   PubMed Web of Science ®Google Scholar
• RenfroLSnowJSOcular effects of topical and systemic steroidsDermatol Clin19921035055121617809
   PubMed Web of Science ®Google Scholar
• McgheeCNDeanSDanesh-MeyerHLocally administered ocular corticosteroids: benefits and risksDrug Saf2002251335511820911
   PubMed Web of Science ®Google Scholar
• GaudanaRJwalaJBodduSHMitraAKRecent perspectives in ocular drug deliveryPharm Res20092651197121618758924
   PubMed Web of Science ®Google Scholar
• LiuSJonesLGuFXNanomaterials for ocular drug deliveryMacromol Biosci201212560862022508445
   PubMed Web of Science ®Google Scholar
• YuanXMarcanoDCShinCSOcular drug delivery nanowafer with enhanced therapeutic efficacyACS Nano2015921749175825585134
   PubMed Web of Science ®Google Scholar
• SoutoEBDoktorovovaSGonzalez-MiraEEgeaMAGarciaMLFeasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugsCurr Eye Res201035753755220597640
   PubMed Web of Science ®Google Scholar
• SwaminathanSVaviaPRTrottaFCavalliRNanosponges encapsulating dexamethasone for ocular delivery: formulation design, physico-chemical characterization, safety and corneal permeability assessmentJ Biomed Nanotechnol201396998100723858964
   PubMed Web of Science ®Google Scholar
• KalamMADevelopment of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasoneInt J Biol Macromol20168912713627126165
   PubMed Web of Science ®Google Scholar
• NagaiNNakazawaYItoYKanaiKOkamotoNShimomuraYA Nanoparticle-Based Ophthalmic Formulation of Dexamethasone Enhances Corneal Permeability of the Drug and Prolongs Its Corneal Residence TimeBiol Pharm Bull20174071055106228674248
   PubMedGoogle Scholar
• RomeroGBKeckCMMüllerRHBou-ChacraNADevelopment of cationic nanocrystals for ocular deliveryEur J Pharm Biopharm201610721522227388629
   PubMed Web of Science ®Google Scholar
• ZhangZYuJZhouYSupramolecular nanofibers of dexamethasone derivatives to form hydrogel for topical ocular drug deliveryColloids Surf B Biointerfaces201816443644329438842
   PubMed Web of Science ®Google Scholar
• AnLShah GilaniMRLiangGGilaniHSRehanMPeptide-based nanostructures for cancer diagnosis and therapyCurr Med Chem201421212453246624524760
   PubMedGoogle Scholar
• DuXZhouJShiJXuBSupramolecular hydrogelators and hydrogels: from soft matter to molecular biomaterialsChem Rev201511524131651330726646318
   PubMed Web of Science ®Google Scholar
• MeiBMiaoQTangALiangGEnzyme-instructed self-assembly of taxol promotes axonal branchingNanoscale2015738156051560826359218
   PubMedGoogle Scholar
• SundarSChenYTongYWDelivery of therapeutics and molecules using self-assembled peptidesCurr Med Chem201421222469247924358972
   PubMedGoogle Scholar
• VemulaPKWiradharmaNAnkrumJAMirandaORJohnGKarpJMProdrugs as self-assembled hydrogels: a new paradigm for biomaterialsCurr Opin Biotechnol20132461174118223465753
   PubMedGoogle Scholar
• YangCWangZOuCChenMWangLYangZA supramolecular hydrogelator of curcuminChem Commun2014506694139415
   PubMed Web of Science ®Google Scholar
• GyntherMLaineKRopponenJLarge neutral amino acid transporter enables brain drug delivery via prodrugsJ Med Chem200851493293618217702
   PubMed Web of Science ®Google Scholar
• PochopinNLCharmanWNStellaVJAmino acid derivatives of dapsone as water-soluble prodrugsInt J Pharm19951212157167
   Google Scholar
• SanterVdel Río SanchoSLaptevaMKaliaYNTargeted intracorneal delivery-Biodistribution of triamcinolone acetonide following topical iontophoresis of cationic amino acid ester prodrugsInt J Pharm20175251435328414134
   PubMedGoogle Scholar
• AdelliGRBhagavPTaskarPDevelopment of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular BioavailabilityInvest Ophthalmol Vis Sci20175842167217928399267
   PubMedGoogle Scholar
• LiJKuangYGaoYduXShiJXuBD-amino acids boost the selectivity and confer supramolecular hydrogels of a nonsteroidal anti-inflammatory drug (NSAID)J Am Chem Soc2013135254254523136972
   PubMed Web of Science ®Google Scholar
• LinRCuiHSupramolecular nanostructures as drug carriersCurr Opin Chem Eng201577583
   Web of Science ®Google Scholar
• MaWCheethamAGCuiHBuilding Nanostructures with DrugsNano Today2016111133027066106
   PubMedGoogle Scholar
• WangYCheethamAGAngacianGSuHXieLCuiHPeptide-prug conjugates as effective prodrug strategies for targeted deliveryAdv Drug Deliver Rev2011110112126
   Google Scholar
• RautioJKumpulainenHHeimbachTProdrugs: design and clinical applicationsNat Rev Drug Discov20087325527018219308
   PubMed Web of Science ®Google Scholar
• RautioJKärkkäinenJSloanKBProdrugs – Recent approvals and a glimpse of the pipelineEur J Pharm Sci201710914616128782609
   PubMed Web of Science ®Google Scholar
• HamadaYRecent progress in prodrug design strategies based on generally applicable modificationsBioorg Med Chem Lett20172781627163228285913
   PubMedGoogle Scholar
• AbetVFilaceFRecioJAlvarez-BuillaJBurgosCProdrug approach: An overview of recent casesEur J Med Chem201712781082727823878
   PubMed Web of Science ®Google Scholar
• SugawaraMHuangWFeiYJLeibachFHGanapathyVGanapathyMETransport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2J Pharm Sci200089678178910824137
   PubMed Web of Science ®Google Scholar
• DiasCNashedYAtluriHMitraAOcular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MSCurr Eye Res200225424325212658558
   PubMed Web of Science ®Google Scholar
• VigBSHuttunenKMLaineKRautioJAmino acids as promoieties in prodrug design and developmentAdv Drug Deliv Rev201365101370138523099277
   PubMed Web of Science ®Google Scholar
• DobrovolskaiaMAPatriAKZhengJInteraction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profilesNanomedicine20095210611719071065
   PubMed Web of Science ®Google Scholar
• BararJJavadzadehAROmidiYOcular novel drug delivery: impacts of membranes and barriersExpert Opin Drug Deliv20085556758118491982
   PubMed Web of Science ®Google Scholar
• RatayMLBellottiEGottardiRLittleSRModern Therapeutic Approaches for Noninfectious Ocular Diseases Involving InflammationAdv Healthc Mater20176231700733
   Google Scholar
• Sánchez-LópezEEspinaMDoktorovovaSSoutoEBGarcíaMLLipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part I – Barriers and determining factors in ocular deliveryEur J Pharm Biopharm2017110707527789358
   PubMed Web of Science ®Google Scholar